Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

TenNor Receives Orphan Drug Designation in the US for Biofilm Infection Candidate

publication date: Jan 20, 2020

Suzhou's TenNor Therapeutics received Orphan Drug Designation in the US for its novel antibacterial, TNP-2092, as a treatment for biofilm infections on prosthetic joints. The company says biofilm infections are extremely difficult to treat, often requiring surgical intervention plus prolonged antibiotic therapy. In November 2019, TenNor reported positive top-line results from a US Phase II trial of TNP-2092 in patients with acute bacterial skin and skin structure infection (ABSSSI). TenNor focuses on developing novel products for rare diseases associated with bacterial infections. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital